Loading stock data…
Teva Pharmaceutical Industries (TEVA)
$30.81-0.37 (-1.19%)
Market ClosedLast close Jul 24
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Teva Pharmaceutical Industries Limited in the Healthcare sector is trading at $30.81 with a market capitalization of $38.2B. Wall Street consensus targets $40.90 (10 analysts), implying a +32.7% move over the next 12 months. The stock is currently 18% below its 52-week high of $37.35, remaining 1.4% above its 200-day moving average. On fundamentals, Piotroski 9/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +32.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 24) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.98B↓ | $4.71B↑ | $4.48B↑ | $4.18B↑ | $3.89B |
| Gross Profit | $1.97B↓ | $2.66B↑ | $2.30B↑ | $2.10B↑ | $1.88B |
| Operating Income | $759.00M↓ | $1.27B↑ | $1.07B↑ | $899.00M↑ | $706.00M |
| Net Income | $369.00M↓ | $480.00M↑ | $433.00M↑ | $282.00M↑ | $214.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$38.23B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.50
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.01%
Volume
Today's trading volume
2.74M
Recent News
Why Teva Pharmaceutical Stock Is a Buy Despite Trump Tariff Threat
President Donald Trump’s threat of 100% tariffs on generic drugs would seem to be a problem for Teva Pharmaceutical. It might not be.
Dr. Reddy's Laboratories Q1 Earnings Call Highlights
Dr. Reddy's Laboratories (NYSE:RDY) reported a year-over-year revenue decline and sharply lower profitability for the first quarter of fiscal 2027, as lower lenalidomide sales and semaglutide API-related challenges weighed on results. Management said the company’s base business, excluding lenalidomi
Hoka Expected to Drive First Quarter Earnings Results for Deckers, Analysts Say
Wall Street expects Hoka's revenue growth to help Deckers exceed both guidance and consensus expectations.
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.
Teva Pharmaceutical Industries (TEVA) Could Be 21% Below Fair Value On Vitiligo Trial Progress
Teva Pharmaceutical Industries (NYSE:TEVA) has drawn fresh attention after announcing that its investigational anti IL 15 antibody, TEV 408, will progress to a Phase 2b vitiligo trial following encouraging Phase 1b data. See our latest analysis for Teva Pharmaceutical Industries. That progress has arrived after a powerful run in Teva Pharmaceutical Industries, where the 1 year total shareholder return is about 96% and the 5 year total shareholder return is roughly 2.8x. This comes even as the...